Fast Five Quiz: Melanoma Treatment

Chih-Shan Jason Chen, MD, PhD


January 24, 2020

In patients with stage III melanoma, the overall risk for relapse is 50% over 5-10 years. Thus, adjuvant therapy should be considered in any patients with stage III A, B, C, or D disease, as well as in patients with resected stage IV disease. When choosing to treat with adjuvant therapy, clinicians should consider several factors, including stage, burden of disease, comorbidities, and age.

Learn more about adjuvant therapy for melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.